Abstract:Our results showed that this new chip had an important clinical value of patients with metastatic breast cancer.CTCs count showed good prospects in monitoring cancer prognosis and guiding future individualized treatment.We have manufactured a new microfluidic chip to isolate and identify CTCs and CTCs clusters with high throughput.Circulating tumor cells (CTCs) existing in peripheral blood can be used to predict the prognosis and survival of cancer patients. The study was designed to detect circulating tumor cells and circulating tumor single cell genes by applying microfluidic chip technology. It was used to explore the clinical application value in breast cancer.We have developed a size-based CTCs sorting microfluidic chip, which contains a hexagonal array and a micro-pipe channel array to isolate and confirm both single CTCs and CTCs clusters. The sorting performance of the as-fabricated chip was tested by analyzing the clinical samples collected from 129 breast cancer patients and 50 healthy persons.In this study, the chip can detect different immunophenotypes of CTCs in breast cancer patients. It was found that the new microfluidic device had high sensitivity (73.6%) and specificity (82.0%) in detecting CTCs. By detecting the blood samples of 129 breast cancer patients and 50 healthy blood donors, it was found that the number of CTCs was not associated with clinical factors such as age, gender, pathological type, and tumor size of breast cancer patients (P > 0.05), but was associated with TNM staging of breast cancer, with or without metastasis (P < 0.005). There was a statistically significant difference in the number of CTCs between luminal A (ER+/PR+/HER2-) and HER-2+ (ER-/PR-/HER2+) (P < 0.05). The best cut-off level distinguished by CTC between the breast cancer patients and the healthy persons was 3.5 cells/mL, with 0.845 for AUC-ROC, 0.790–0.901 for 95% CI, 73.6% for sensitivity, and 82% for specificity (P = 0.000). The combination of CTC, CEA, CA125 and CA153 can provide more effective breast cancer screening.The CTCs analysis method presented here doesn't rely on the specific antibody, such as anti-EpCAM, which would avoid the missed inspection caused by antibody-relied methods and offer more comprehensive biological information for clinical breast cancer diagnosis and treatment.

Research of the Reliability of Tissue Chip with Immunohistochemistry in Breast Cancer

Analysis of the reliability of tissue microarray in the research of prostate cancer

Reliability of Tissue Microarrays for Immunohistochemical Detecting of Tumor Markers in Non-Small Cell Lung Cancer

Tissue chip and ISH analysis of hTER mRNA and hTERT mRNA expressions in different human tumor types

A Comparative Study on the Expression of ER,PR and Nm23 in Breast Carcinoma by Tissue Microarray with Usual Section

Comparative Study Between Bio-chip Detection and Chemiluminescent Immunoassay for Multi-tumor Markers

The Development and Application of Tissue Chip

Study of Expression and Correlation of CD44v9 Mrna and Ki-67 in Breast Cancer by Tissue Chip

Comparision of HER2/neu Oncogene Detected by Chromogenic In-Situ Hybridization and Immunohistochemistry in Breast Cancer

A protein chip system for parallel analysis of multi-tumor markers and its application in cancer detection.

Immunofluorescence Analysis of Breast Cancer Biomarkers Using Antibody-Conjugated Microbeads Embedded in a Microfluidic-Based Liquid Biopsy Chip

Initial Study on Thymidine Phosphorylase in Breast Cancer Tissue by Optical Protein Chip

A label-free microfluidic chip for the highly selective isolation of single and cluster CTCs from breast cancer patients

Clinical analysis of multi-tumor markers proteinchip system(C12)

By using tissue chip technique to analysis the expression of Ubiquitin,Skp2 and p27 in lung cancer

The coincidence study on the relationship between serum HER-2 concentration and tissue HER-2 level in patients with relapsed breast cancer

[Intralaboratory Reproducibility of HER2 Testing in Breast Cancer by Immunohistochemistry and Comparison of Results Obtained by Different Assays].

Metas-Chip precisely identifies presence of micrometastasis in live biopsy samples by label free approach

Study on the Expression of Rb Gene in Primary Hepatocellular Carcinoma by Tissue Chip

[Reliability of Estrogen Receptor, Progesterone Receptor and Human Epidermal Growth Factor Receptor 2 Expression in Breast Cancer Evaluated by Immunohistochemistry].